Jon P. Stonehouse - 19 Dec 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: President & CEO, Director
Signature: /s/ Alane P. Barnes, by power of attorney
Issuer symbol: BCRX
Transactions as of: 19 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 21 Dec 2022, 15:38:35 UTC
Previous filing: 19 Dec 2022
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Award	$0	+127,500	+14%	$0.000000	1,015,230	19 Dec 2022	Direct	F1
holding	BCRX	Common Stock						5,000	19 Dec 2022	By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
holding	BCRX	Common Stock						5,000	19 Dec 2022	By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Emp. Stock Option (Right to Buy)	Award	$0	+595,000		$0.000000	595,000	19 Dec 2022	Common Stock	595,000	$10.63	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2	Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.